Neoadjuvant endocrine therapy for strongly hormone receptor-positive and HER2-negative early breast cancer: results of a prospective multi-center study

被引：0

作者：

Xinguang Wang

Zhaoqing Fan

Xing Wang

Yingjian He

Yiqiang Liu

Xiang Wang

Bailin Zhang

Zefei Jiang

Tao Wang

Zhigang Yu

Fei Wang

Yinhua Liu

Yanping Li

Jianguo Zhang

Bin Luo

Hongchuan Jiang

Tianfeng Wang

Yuntao Xie

Jinfeng Li

Tao Ouyang

机构：

[1] Peking University Cancer Hospital & Institute,Breast Center, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education)

[2] Peking University Cancer Hospital & Institute,Department of Pathology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education)

[3] National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Department of Breast Surgical Oncology

[4] Chinese Academy of Medical Sciences and Peking Union Medical College,Department of Oncology

[5] The Fifth Medical Center of PLA General Hospital,Department of Breast Surgery, Cheeloo College of Medicine, The Second Hospital

[6] Shandong University,Breast Disease Center

[7] Peking University First Hospital,Department of Breast Surgery, Beijing Shijitan Hospital

[8] Capital Medical University,Department of Breast Surgery

[9] The Second Hospital of Harbin Medical University,Department of General Surgery, Clinical School of Medicine, Tsinghua Changgung Hospital

[10] Tsinghua University,Department of Breast Surgery, Beijing Chao Yang Hospital

[11] Capital Medical University,undefined

来源：

Breast Cancer Research and Treatment | 2022年 / 195卷

关键词：

Neoadjuvant endocrine therapy; Breast cancer; Pathological response; Survival;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：301 / 310

页数：9

共 50 条

[41] Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer
Gaia Griguolo
Maria Vittoria Dieci
Laia Paré
Federica Miglietta
Daniele Giulio Generali
Antonio Frassoldati
Luigi Cavanna
Giancarlo Bisagni
Federico Piacentini
Enrico Tagliafico
Katia Cagossi
Guido Ficarra
Aleix Prat
Pierfranco Conte
Valentina Guarneri
npj Breast Cancer, 7
[42] Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
Ditsch, Nina
Schmidt, Marcus
GEBURTSHILFE UND FRAUENHEILKUNDE, 2019, 79 (12) : 1328 - 1335
[43] Evolving treatment patterns in hormone receptor-positive, HER2-negative metastatic breast cancer
Lankford, M. L.
Britton, S. L.
Buettner, A. D.
Scharf, M.
Tiscione, B.
Willey, J. P.
Mahtani, R. L.
CANCER RESEARCH, 2019, 79 (04)
[44] Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer
Griguolo, Gaia
Dieci, Maria Vittoria
Pare, Laia
Miglietta, Federica
Generali, Daniele Giulio
Frassoldati, Antonio
Cavanna, Luigi
Bisagni, Giancarlo
Piacentini, Federico
Tagliafico, Enrico
Cagossi, Katia
Ficarra, Guido
Prat, Aleix
Conte, Pierfranco
Guarneri, Valentina
NPJ BREAST CANCER, 2021, 7 (01)
[45] Progression-free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-positive HER2-negative metastatic breast cancer
Corbaux, Pauline
Lardy-Cleaud, Audrey
Alexandre, Marie
Fontanilles, Maxime
Levy, Christelle
Viansone, Alessandro Adriano
Mailliez, Audrey
Debled, Marc
Goncalves, Anthony
Le Du, Fanny
Lerebours, Florence
Ferrero, Jean-Marc
Eymard, Jean-Christophe
Mouret-Reynier, Marie-Ange
Petit, Thierry
Frenel, Jean-Sebastien
Dalenc, Florence
Courtinard, Coralie
Chaix, Marie
Bachelot, Thomas
BREAST CANCER RESEARCH AND TREATMENT, 2022, 191 (01) : 191 - 207
[46] Inflammatory response to neoadjuvant endocrine therapy in hormone receptor-positive breast cancer
Oner, G.
Van Berckelaer, C.
Praet, M.
Canturk, N. Z.
Altintas, S.
Tjalma, W.
Berneman, Z.
Peeters, M.
Pauwels, P.
van Dam, P. A.
EUROPEAN JOURNAL OF CANCER, 2024, 200 : 79 - 80
[47] Overall survival and progression-free survival with endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: review
Reinert, Tomas
Barrios, Carlos H.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2017, 9 (11) : 693 - 709
[48] Endocrine therapy and palbociclib within a compassionate use program in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer
Maurer, Christian
Ferreira, Arlindo R.
Martel, Samuel
Lambertini, Matteo
Ponde, Noam
Aftimos, Philippe
de Azambuja, Evandro
Piccart, Martine
BREAST, 2018, 39 : 14 - 18
[49] Progression-free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-positive HER2-negative metastatic breast cancer
Pauline Corbaux
Audrey Lardy-Cleaud
Marie Alexandre
Maxime Fontanilles
Christelle Lévy
Alessandro Adriano Viansone
Audrey Mailliez
Marc Debled
Anthony Goncalves
Fanny Le Du
Florence Lerebours
Jean-Marc Ferrero
Jean-Christophe Eymard
Marie-Ange Mouret-Reynier
Thierry Petit
Jean-Sébastien Frenel
Florence Dalenc
Coralie Courtinard
Marie Chaix
Thomas Bachelot
Breast Cancer Research and Treatment, 2022, 191 : 191 - 207
[50] Abemaciclib and endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: A real-world UK multicentre experience
Battisti, Nicolo Matteo Luca
Morrison, Laura
Nash, Tamsin
Senthivel, Nishanti
Kestenbaum, Samantha
Begum, Parvin
Obeid, Mariam
Hayhurst, William
Yang, Dorothy
Gafoor, Shafiah
Brown, Caroline
Rehman, Farah
Kenny, Laura
Hatcher, Olivia
Susan, Susan
Williams, Jennet
Brown, Anna
Rozati, Hamoun
Alexandros, Alexandros
Sawyer, Elinor
Gousis, Charalampos
Karapanagiotou, Eleni
Rigg, Anna
Rapti, Kleopatra
Roylance, Rebecca
Beresford, Mark
Gee, Abigail L.
Konstantis, Apostolos
King, Judy
Nathan, Mark
Spurrell, Emma
Pearce, Mark
Bradwell, Dane
Denton, Arshi
Swain, Kate
McGrath, Sophie
Allen, Mark
Ring, Alistair
Johnston, Stephen
Raja, Fharat
CANCER RESEARCH, 2022, 82 (04)

← 1 2 3 4 5 →